Human epidermal growth factor receptor 2 (HER2), epithelial cell adhesion molecule (EpCAM), and mesothelin (MSLN) antigens along with NK group 2 member D ligand (NKG2DL), MUC-1, and CD133 have been licensed for use in clinical trials (Table 2) because they are among the most overexpressed antigens in patients with CRC (107). The gene discussed is PROM1; the disease is colorectal carcinoma.